Summary by Futu AI
Mangoceuticals, Inc. has been actively engaging in corporate developments throughout the first half of 2024, including the issuance of securities, entering consulting and employment agreements, and other significant corporate activities. The company has issued shares of restricted common stock as compensation in consulting agreements with entities such as Luca Consulting, LLC, First Level Capital, and G&P General Consulting. Key employment agreements have been executed, including an extension with Luca Consulting, LLC, and a new agreement with Zvonimir Moric for strategic partnership development. Mangoceuticals also completed a follow-on offering of common stock and exercised an over-allotment option, which included the issuance of warrants to underwriters. The company designated Series B and C Convertible Preferred Stock, with sales of Series...Show More